Type: WKAP Radar Feed

WKAP Radar Feed - 2026 - 10 - 08

Market date: 2026-10-08
Canonical URL: https://wkap.ai/radar/wkap-radar-feed-2026-10-08.html

WKAP Radar Feed

*October 8, 2026*

*Orders Can Survive Competition While Margins Do Not*

*3 Thesis Objects: AEHR, TER, FORM*

Preheader:

Make your AI track X alpha.

WKAP Feed compresses earnings inflections, KOL flow, supply-chain
bottlenecks, and short-duration attention into daily AI-ready context.

Set up your AI to read this Feed.

Ask:

“What did I miss?”

## HUMAN USER — START HERE

Reopen competitive assumptions, not every testing supplier's earnings
forecast. Rank AEHR > TER > FORM for incremental competitive-risk
research urgency: Aehr has approximately $6m of follow-on Sonoma
orders; Teradyne has enhanced Titan HP burn-in deployed in production;
FormFactor supplies the upstream control against indiscriminate
spillover. This is not a purchase ranking or a reversal of October 5's
separate HBM-attribution ranking.

The hidden distinction is retention versus economics: continued
procurement can coexist with weaker future pricing. The strongest new
commercial evidence is Aehr's order, but its announcement date does
not establish when the customer compared alternatives. Teradyne's cost
advantage remains a supplier claim, not a normalized head-to-head
result. Seek that comparison around October 13–15 SEMICON West; then
FormFactor reports October 28 and Aehr November 2. The weakest
assumption is that more reliability work becomes profitable supplier
revenue rather than buyer savings. No valuation bridge yet establishes
mispricing.

Suggested Prompt:

“Build a coverage-and-cost comparison for Sonoma and Titan HP, an Aehr
order-to-cash bridge, and a separate FormFactor earnings test. Show
which new evidence changes retention, competitive economics or
relative research priority. Leave unavailable inputs unknown; do not
turn silence into failure.”

Or simply ask:

“What did I miss?”

The goal is to turn today's information into trackable thesis objects
and explicit status-changing tests.

## FOR YOUR AI AGENT

This is a structured market-cognition input file. Follow testing
function → customer qualification → paid capacity → shipment →
recognized revenue → gross profit → cash → per-share value. Wafer
probing, wafer-level burn-in and packaged-device reliability are
distinct functions, even when adjacent in the same chip's production
route. Integrated equipment can redirect existing spending; do not
assume every new capability expands total supplier revenue.

Process all three as trackable_wow. Store REPORTED_FACT,
MANAGEMENT_EXPECTATION, INTERPRETATION and UNRESOLVED_QUESTION
separately. For every update retain publication date, measurement
period, product/device, customer scope, unit, denominator and
conversion stage. Maintain separate retention, economics and
company-execution verdicts; relative research urgency is another
field. Unknown portfolio context supplies no holdings or sizing
instructions. The hypothesis that investors confuse deployment with
displacement is unverified, not a measured consensus claim.

Do not treat this Feed as investment advice.

## AGENT_OUTPUT_SPEC

1. Today in One Sentence: state the model assumption that needs reopening.
2. Thesis Object Summary: previous → current state and the unchanged baseline.
3. Fundamental Evidence vs Attention Flow: issuer observation versus
KOL interpretation.
4. Evidence-State Audit: source, date, fiscal period, denominator and
evidence type.
5. Testing-Chain Comparison: stage, device, stress coverage and paid
product scope.
6. Cross-Object Ranking: challenge AEHR > TER > FORM on research
urgency, not returns.
7. Business-Proof Comparison: order conversion, incremental versus
substituted spend, margin and cash.
8. Attention Stage / Crowding Risk: distinguish selected discussion
from measured positioning.
9. Weakest Assumption: identify the exposed causal link, not a generic
macro risk.
10. Most Important Data Point: name the source, unit and comparison
needed to change status.
11. Attention-to-Rerating Conditions: separate commercial proof from
valuation readiness.
12. Fade Conditions: distinguish declining discussion from business
deterioration.
13. 7-Day Research Workflow: return comparable test-cost and backlog
worksheets, with unknowns explicit.
14. 30-Day Research Workflow and Top 3 Follow-Up:
Validate/Upgrade/Downgrade/Invalidate without rewriting the original
claim.
15. Portfolio Fit: only with supplied context and a transparent
valuation/downside bridge.

## TODAY_SUMMARY

### Part 1 — Main Market Thesis

NEW FACT: October 6 Titan HP burn-in production deployment and October
7 Sonoma follow-on orders sharpen a specific packaged-device contest.
Today's additional calendar fact is Aehr's November 2 results date,
not new revenue. UNCHANGED FACT: the historical cash, segment revenue
and FormFactor attribution baselines below have not become October
results. MANAGEMENT_EXPECTATION: scheduled deliveries and future ramps
remain prospective. INTERPRETATION: replace assumed pricing safety
with a measurable retention-economics test. UNRESOLVED_QUESTION: who
captures the value of additional screening, and how much is
incremental rather than transferred spending?

### Part 2 — Today’s Thesis Objects

AEHR — Fundamental: approximately $6m of systems, modules, sockets and
software for the existing lead customer's second AI processor;
delivery over six months. Attention: retained procurement does not
establish exclusivity or protected pricing. Primary:
https://www.aehr.com/2026/10/aehr-receives-follow-on-sonoma-production-orders-for-lead-hyperscale-customer-s-next-generation-ai-processor/

TER — Fundamental: enhanced Titan HP burn-in is available and
production-deployed, without disclosed incremental revenue or
displacement. Attention: process overlap is narrower than a
company-wide substitution claim. Primary:
https://investors.teradyne.com/news-events/press-releases/detail/452/teradyne-introduces-titan-hp-platform-with-burn-in-capabilities-for-advanced-ai-data-center-devices

FORM — Fundamental: October 28 reporting date; operating evidence
unchanged. Attention: additional test steps and duration must outweigh
parallel-testing productivity before becoming supplier revenue.
Primary: https://investors.formfactor.com/news-releases/news-release-details/formfactor-announce-third-quarter-2026-financial-results-october

### Part 3 — Attention Flow Today

Three independent research sources supply different questions: Photon
Capital asks about retention and pricing; Schulz Duggan localizes
product overlap; Carrio introduces the productivity offset. They are
interpretations, not three confirmations of customer switching.
Priority attention source:
https://x.com/PhotonCap/status/2107858654481490184 . No holding
disclosure was visible in the selected posts or visible bios when
checked at approximately 19:34–19:35 ICT. That does not prove absence
of financial interests. No broad positioning or crowding dataset was
established.

### Part 4 — The Better Question

Which paid testing step changes hands, at what comparable coverage and
cost, and does retained business still produce adequate gross profit
and cash? A share conclusion needs a defined market denominator; a
stock conclusion additionally needs valuation. Neither can be
manufactured from launch language or one incumbent order.

## MARKET_REGIME

RISK_TONE: Thesis-specific caution; no market-wide risk-on/off
classification inferred from these three quotes.
MAIN_DRIVER: Expensive AI packages make defect detection economically
valuable, while integration and competition may transfer savings to
buyers.
MARKET_CONTEXT: U.S. premarket observations, not October 8 closing
prices. Prices identify the reference session; they do not establish
price causation, intrinsic value or an entry recommendation.
ATTENTION_ENVIRONMENT: A new deployed capability is meeting an
incumbent's subsequent order announcement. Procurement timing and
comparable coverage remain missing.
WKAP_VIEW: Keep sales retention, economics and relative urgency
separate. FORM's upstream position limits this particular spillover
inference; it does not immunize FORM against competition or
productivity gains.

## STATE_CHANGE_LEDGER

Object | Previous state | Current state | Model update permitted |
Update prohibited
AEHR | Second processor program already won; conversion pending | New
follow-on Sonoma capacity orders, with six-month deliveries | Increase
evidence of continued procurement within that program | New-customer
claim, exclusivity, protected price, or contemporaneous win against
Titan
TER | Platform competition discussed as a risk | Issuer says enhanced
burn-in is deployed in production | Move capability from prospective
to deployed | Infer burn-in customer count from prior SLT customers,
or book segment revenue as Titan sales
FORM | Filed HBM-related DRAM increment and prospective Q3 guide |
Same operating baseline; October 28 test now scheduled | Set the
financial/attribution retrieval checkpoint | Treat calendar notice as
demand acceleration or guide reaffirmation

Aehr's October 8 November 2 notice supplies a second confirmed
financial checkpoint. It does not retroactively change the timing of
the October 7 order or prove shipment recognition.

## CROSS_OBJECT_EVIDENCE_MATRIX

Object | Best hard evidence | Numerical baseline and vintage | Missing
bridge | Most useful worksheet
AEHR | Disclosed Sonoma follow-on order | Approximately $6m October 7;
FY2026 operating cash used $3.3m and stock issuance $97.4m | Delivery
→ recognized revenue → product/customer gross profit → cash | Dated
order/backlog reconciliation with overlap and cancellation controls
TER | Issuer-reported production deployment | Q2 Semiconductor Test
revenue $1.1218bn; consolidated Q3 guide $1.2–1.3bn versus Q2 $1.329bn
| Comparable capability → paid adoption → incremental profit |
Coverage, throughput and total cost per screened device on matched
workloads
FORM | Filed DRAM growth attribution | June-quarter DRAM $84.999m
versus $57.057m; about 75% of increase attributed to HBM | New
attributable mix → matching-definition margin | DRAM/HBM and
Triton/Systems split plus adjusted-margin reconciliation

AEHR filing: https://www.sec.gov/Archives/edgar/data/1040470/000165495426006919/aehr_10k.htm
TER filing: https://investors.teradyne.com/sec-filings/all-sec-filings/content/0001193125-26-327715/ter-20260628.htm
TER guide: https://investors.teradyne.com/news-events/press-releases/detail/445/teradyne-reports-second-quarter-2026-results
FORM filing: https://investors.formfactor.com/node/20681/html
FORM guide: https://investors.formfactor.com/news-releases/news-release-details/formfactor-inc-reports-2026-second-quarter-results

Arithmetic control: FORM's DRAM increment is $27.942m; approximately
75% implies about $20.96m of that increment, not total HBM sales. The
remainder and Triton must stay separate. AEHR's $80.6m backlog in the
annual filing is dated May 29: adding subsequent orders without
shipments, removals and overlap does not produce a current balance.
TER's unchanged guide is not an October cut.

## RANKED_UNANSWERED_QUESTIONS

1. AEHR: does continued program procurement preserve economics?
Request shipment/recognition, customer-product mix and margin
evidence. Until then retention is supported narrowly; pricing
resilience is unresolved.
2. TER: what is the comparable cost advantage and commercial scale?
Require workload, stress duration, coverage, utilization, throughput
and customer/program scope before interpreting supplier efficiency
claims.
3. FORM: does the October 28 result validate execution and separately
refresh HBM/Triton attribution? Aggregate growth without attribution
answers only the first question.

Shared hardest gap: customer qualification/procurement dates and
mutually comparable coverage may never be public. Record that boundary
explicitly; do not replace it with chronology of press releases or KOL
confidence.

Urgency rule: compare the materiality of the open model decision, the
next actionable disclosure and whether a feasible missing input could
change that decision. AEHR leads because a disclosed retained program
exposes a direct revenue-to-profit uncertainty; TER follows because
commercial scale is still unquantified; FORM's distinct forecast has
no new operating shock. For every proposed adjacent-pair reversal
return: pair | open model cell | new evidence | potential consequence
| next disclosure | retrievable missing input | each object's
unchanged/changed state | reason to spend the next research hour
differently. A positive result may close a question and reduce
urgency, or open a larger measurable question and raise it. Require
that explanation; neither good news nor peer silence alone changes the
order.

## SCENARIO_BRANCHES

Retention with weaker economics: AEHR ships and recognizes sales, but
disclosed mix-adjusted profitability deteriorates. Retention can
remain supported while economic resilience weakens; this is not
evidence of a lost customer. Investigate competitive causation rather
than assume it.

Credible entrant conversion: TER discloses paid program scale and
comparable coverage/cost economics while AEHR's margin bridge remains
unresolved. TER can move ahead in the research queue. A named
displaced supplier would strengthen the share conclusion, but is not
necessary to investigate incremental earnings.

Incumbent conversion: AEHR reconciles delivery, recognition, backlog
and profit without deterioration; TER still lacks quantified
economics. Close the most urgent AEHR uncertainty, potentially
lowering its research urgency even as its absolute thesis improves.
Rank changes are not automatic upgrades or downgrades.

Independent upstream shock: FORM's result materially changes execution
or attribution. Raise its research urgency independently; a joint
revenue/margin miss is not evidence Titan caused it. No new commercial
data for the burn-in pair means pending, not invalidated.

## ATTENTION_TRADE_BOARD

Attention Trade Board

WKAP Attention View: strongest disclosed commercial fact is AEHR's
order; cleanest analytical asymmetry is retained sales versus unproven
margins; largest optionality gap is TER's unquantified commercial
opportunity. Most crowded is unknown. Highest narrative fade risk is
TER if deployment is repeatedly presented as revenue. Best
durable-thesis candidate cannot be chosen on these attention signals
alone; comparable economics and valuation remain necessary.

## RADAR_OBJECT_INDEX

THESIS_OBJECT_1: AEHR
THEME: Packaged-device burn-in / retained-program economics
STATUS: active_trackable — priority 1 for incremental competitive-risk research
POSITION_CONTEXT: [not provided]
PRICE_AT_PUBLISH: $87.00 USD, October 8 U.S. premarket, as of 08:31:32
EDT /19:31:32 ICT; rechecked by 19:43:26 ICT. Last October 7 regular
close $89.37. https://finance.yahoo.com/quote/AEHR/
DATE_FIRST_ADDED_TO_RADAR: 2026-07-09
SETUP_TYPE: Order-backed retention versus unverified economic resilience
ATTENTION_STAGE: Commercial fact → competitive-margin diligence
ATTENTION_WINDOW: 7–30-day research; six-month delivery horizon remains longer
KEY_QUESTION: What profit and cash accompany retained procurement?

THESIS_OBJECT_2: TER
THEME: Integrated burn-in / commercial-scale proof
STATUS: active_trackable — priority 2; deployed capability, economics pending
POSITION_CONTEXT: [not provided]
PRICE_AT_PUBLISH: $402.00 USD, October 8 U.S. premarket, as of
08:39:58 EDT /19:39:58 ICT; rechecked by 19:43:26 ICT. Last October 7
regular close $411.78. https://finance.yahoo.com/quote/TER/
DATE_FIRST_ADDED_TO_RADAR: 2026-10-05
SETUP_TYPE: Deployed capability awaiting attributable adoption and profit
ATTENTION_STAGE: Product deployment → financial conversion
ATTENTION_WINDOW: October 13–15 information opportunity; commercial
timing unresolved
KEY_QUESTION: How much comparable customer value becomes incremental
TER earnings?

THESIS_OBJECT_3: FORM
THEME: Upstream wafer probing / independent earnings test
STATUS: active_trackable — priority 3; unchanged operating evidence
POSITION_CONTEXT: [not provided]
PRICE_AT_PUBLISH: $138.00 USD, October 8 U.S. premarket, as of
08:33:27 EDT /19:33:27 ICT; rechecked by 19:43:26 ICT. Last October 7
regular close $139.80. https://finance.yahoo.com/quote/FORM/
DATE_FIRST_ADDED_TO_RADAR: 2026-10-05
SETUP_TYPE: Scope-control comparison with a scheduled financial checkpoint
ATTENTION_STAGE: Technical interpretation → attribution and execution test
ATTENTION_WINDOW: October 28 results; no new operating result today
KEY_QUESTION: Which earnings engine repeats after test-efficiency offsets?

These are displayed last trades, not executable quotes; fresh
retrieval does not refresh an older trade timestamp. First-added dates
preserve the archive's earliest verified thesis cards, not incidental
ticker mentions or today's re-ranking.

## THESIS OBJECTS

### THESIS_OBJECT_1 — AEHR

CARD_ID: WKAP-RADAR-2026-10-08-AEHR
CARD_TITLE: Defend the Economics, Not Merely the Order
TYPE: trackable_wow
THEME: Packaged-device burn-in / retained-program economics
STATUS: active_trackable — narrow retention supported; profitable
conversion pending
POSITION_CONTEXT: [not provided]
PRICE_AT_PUBLISH: $87.00 USD, October 8 premarket, 08:31:32 EDT
/19:31:32 ICT; rechecked by 19:43:26 ICT;
https://finance.yahoo.com/quote/AEHR/
DATE_FIRST_ADDED_TO_RADAR: 2026-07-09
ATTENTION_STAGE: Order evidence → economic-resilience test
ATTENTION_WINDOW: Seven-day evidence review; November 2 financial
checkpoint; deliveries over six months

WHY_A_READER_CARES_NOW: The strongest retention fact still leaves the
shareholder's margin and cash question unanswered.
PREVIOUS_STATE: Existing lead customer's second processor program
already won; conversion incomplete.
CURRENT_STATE: Approximately $6m of additional Sonoma capacity
ordered, not a new customer or demonstrated win against Titan.
DECISION_OR_MONITORING_PAYOFF: Prioritize the order-to-profit bridge;
withhold a pricing-moat upgrade.

THESIS_SUMMARY

Orders support continued procurement for that program. They do not
disclose exclusivity, price concessions, design competition or future
customer diversification. The new rival makes those omissions more
consequential without cancelling the order.

WKAP_ANGLE

The surface-level frame: another order disproves the competitive risk.
The alternative frame: retention and value capture can diverge.
The key research question: what comparable margin/cash evidence
survives the ramp?

CORE_THESIS

REPORTED_FACT: package-level systems, burn-in modules, sockets and
software are included; scheduled deliveries go to the customer's
Taiwan OSAT partner. MANAGEMENT_EXPECTATION: the second processor
ramps in calendar 2027; the first is already in high-volume
production. INTERPRETATION: recurring-component content may matter,
but the full order cannot be classified as recurring revenue. The
separate FOX-XP wafer-level order is not this Sonoma announcement.

ATTENTION_TRADE_FRAME

Attention Source: Photon Capital;
https://x.com/PhotonCap/status/2107858654481490184
Why Today: The October 7 post separates credible rivalry from
demonstrated customer loss.
Attention Stage: Retention fact meets a margin-risk interpretation.
Attention vs Evidence — Hard evidence: the issuer order and historical
filing, not a verified competitor-price comparison.
Primary sources:
https://www.aehr.com/2026/10/aehr-receives-follow-on-sonoma-production-orders-for-lead-hyperscale-customer-s-next-generation-ai-processor/
; https://www.sec.gov/Archives/edgar/data/1040470/000165495426006919/aehr_10k.htm
Attention / interpretation: sector growth can coexist with weaker
pricing power; no holding disclosure visible.
Attention Path: Order → program continuity → delivery → gross profit and cash.
Attention Asymmetry: Better retention evidence and greater economic
uncertainty coexist.
Crowding Risk: Unmeasured; repeated order headlines could hide
concentration and financing risk.
What Could Sustain Attention: Reconciled shipments, recognized
revenue, maintained economics and new disclosed designs/customers.
What Could Make Attention Fade: Repeating the same program order
without conversion evidence.
Attention-to-Thesis Conversion: Upgrade only the component supported
by new data; retained units alone do not resolve pricing.

WEAKEST_ASSUMPTION: Continued procurement translates into satisfactory
mix-adjusted economics under competition.
MOST_IMPORTANT_DATA_POINT: A dated shipment/recognition/backlog bridge
paired with product/customer margin and cash commentary.
NEXT_DATA_POINT: November 2 results after market close, call 5 p.m.
Eastern, for Q1 ended September 25; October's order postdates that
quarter and must not be assumed recognized in it. New calendar source:
https://www.aehr.com/2026/10/aehr-test-systems-to-announce-first-quarter-fiscal-2027-financial-results-on-november-2-2026/
. Cancellation, material pushout or a disclosed lost next-generation
design weakens conversion; retained sales with worse comparable gross
profit weakens economics separately.

### THESIS_OBJECT_2 — TER

CARD_ID: WKAP-RADAR-2026-10-08-TER
CARD_TITLE: Measure the Deployed Threat Before Booking the Upside
TYPE: trackable_wow
THEME: Integrated burn-in / commercial-scale proof
STATUS: active_trackable — deployment supported; share and incremental
earnings pending
POSITION_CONTEXT: [not provided]
PRICE_AT_PUBLISH: $402.00 USD, October 8 premarket, 08:39:58 EDT
/19:39:58 ICT; rechecked by 19:43:26 ICT;
https://finance.yahoo.com/quote/TER/
DATE_FIRST_ADDED_TO_RADAR: 2026-10-05
ATTENTION_STAGE: Deployment → comparable economics
ATTENTION_WINDOW: October 13–15 SEMICON West; subsequent commercial disclosures

WHY_A_READER_CARES_NOW: Production deployment removes one uncertainty
but leaves the size and profitability of the opportunity unmeasured.
PREVIOUS_STATE: Competitive capability required proof beyond a roadmap.
CURRENT_STATE: Issuer reports deployed enhanced burn-in; no quantified
incremental revenue, burn-in customer count or displaced supplier.
DECISION_OR_MONITORING_PAYOFF: Acknowledge the threat, then demand
matched coverage and commercial scale.

THESIS_SUMMARY

Independent slots, device-temperature control and workload execution
provide a plausible integration mechanism. Savings in handling, floor
space or test time belong initially to the buyer; how much TER
monetizes is a separate commercial question.

WKAP_ANGLE

The surface-level frame: integrated burn-in automatically transfers a
rival's revenue.
The alternative frame: technical coverage, qualification and spending
substitution determine the addressable conversion.
The key research question: what paid adoption is incremental and profitable?

CORE_THESIS

REPORTED_FACT: availability and production deployment are explicit
issuer statements. MANAGEMENT_EXPECTATION: lower testing costs are
claimed by the supplier, not established by a verified independent
comparison. INTERPRETATION: equivalent screening at lower total cost
could influence capacity allocation. UNRESOLVED_QUESTION: actual
coverage equivalence and contract economics. The $1.1218bn segment
baseline is not newly quantified Titan revenue; unchanged consolidated
guidance requires its own execution review.

ATTENTION_TRADE_FRAME

Attention Source: Schulz Duggan;
https://x.com/Schulz_Research/status/2107576569330028695
Why Today: The October 7 post locates the direct overlap around
packaged-device burn-in rather than every upstream or optical process.
Attention Stage: Scope correction → commercial diligence.
Attention vs Evidence — Hard evidence: issuer-reported deployment and
platform features; no public head-to-head customer outcome established
here.
Primary sources:
https://investors.teradyne.com/news-events/press-releases/detail/452/teradyne-introduces-titan-hp-platform-with-burn-in-capabilities-for-advanced-ai-data-center-devices
; https://investors.teradyne.com/sec-filings/all-sec-filings/content/0001193125-26-327715/ter-20260628.htm
Attention / interpretation: localized overlap, not interchangeable
coverage or displaced revenue; no holding disclosure visible.
Attention Path: Capability → qualification → paid adoption →
incremental gross profit.
Attention Asymmetry: A real deployed product can still have an unknown
financial contribution.
Crowding Risk: Unmeasured; supplier feature claims may travel faster
than customer evidence.
What Could Sustain Attention: Comparable workload results, commercial
scale and identifiable earnings contribution.
What Could Make Attention Fade: Recycled specifications without
program or financial detail.
Attention-to-Thesis Conversion: Distinguish customer savings, captured
revenue and substituted legacy spending before updating profit.

WEAKEST_ASSUMPTION: The claimed savings persist under comparable
coverage and can be monetized beyond existing equipment spend.
MOST_IMPORTANT_DATA_POINT: Cost per screened device, coverage and
throughput on matched workloads, plus attributable paid program scale.
NEXT_DATA_POINT: October 13–15 issuer conference materials may add
detail, but attendance promises no order. Evidence of inadequate
coverage or failed cost savings weakens the proposition. Nondisclosure
alone leaves commercial conversion pending.

### THESIS_OBJECT_3 — FORM

CARD_ID: WKAP-RADAR-2026-10-08-FORM
CARD_TITLE: Keep the Upstream Control on Its Own Earnings Test
TYPE: trackable_wow
THEME: Wafer probing / HBM and Triton attribution
STATUS: active_trackable — prior evidence unchanged; next execution test pending
POSITION_CONTEXT: [not provided]
PRICE_AT_PUBLISH: $138.00 USD, October 8 premarket, 08:33:27 EDT
/19:33:27 ICT; rechecked by 19:43:26 ICT;
https://finance.yahoo.com/quote/FORM/
DATE_FIRST_ADDED_TO_RADAR: 2026-10-05
ATTENTION_STAGE: Technical interpretation → separate financial test
ATTENTION_WINDOW: October 28 result and subsequent filing

WHY_A_READER_CARES_NOW: A downstream rivalry is a poor reason to
change an upstream forecast without evidence about that upstream
function.
PREVIOUS_STATE: Filed HBM contribution to DRAM growth and prospective guide.
CURRENT_STATE: Same operating facts; reporting date confirmed, not
guidance reaffirmed.
DECISION_OR_MONITORING_PAYOFF: Preserve the distinct forecast and test
its own execution and attribution.

THESIS_SUMMARY

Probe contacts and packaged-device stress systems collect revenue from
different functions. FORM earns its place as a scope control, not a
fabricated third operating catalyst. Productivity, mix and valuation
still matter even if this specific displacement narrative does not
apply.

WKAP_ANGLE

The surface-level frame: all testing suppliers share the same competitive shock.
The alternative frame: stage-specific economics and separately
attributed earnings determine exposure.
The key research question: does net testing demand translate into
repeatable normalized profit?

CORE_THESIS

REPORTED_FACT: the filing attributes approximately 75% of the DRAM
revenue increase to HBM and Systems growth primarily to Triton
co-packaged-optics testing. MANAGEMENT_EXPECTATION: Q3 revenue
$260–280m and adjusted gross margin 54% ±1.5 points. INTERPRETATION:
distinguish guide delivery from newly attributable growth. An
aggregate DRAM pass does not identify its HBM component.

ATTENTION_TRADE_FRAME

Attention Source: Carrio;
https://x.com/carrioresearch/status/2107385517767643533
Why Today: The October 6 technical Article supplies the productivity
offset missing from a simple more-tests/more-revenue shortcut.
Attention Stage: Engineering explanation → economic validation.
Attention vs Evidence — Hard evidence: filed mix and issuer guide, not
the source's valuation upside or forward estimates.
Primary sources: https://investors.formfactor.com/node/20681/html ;
https://investors.formfactor.com/news-releases/news-release-details/formfactor-inc-reports-2026-second-quarter-results
Attention / interpretation: test volume, steps, duration and cost
interact with parallelism; no holding disclosure visible.
Attention Path: More complex chips → net test work → probe demand →
attributable mix → normalized profit.
Attention Asymmetry: Better scope definition prevents a false
spillover without creating an automatic bullish conclusion.
Crowding Risk: Unmeasured; an HBM label can obscure denominator and
efficiency differences.
What Could Sustain Attention: Fresh attributable mix and
matching-definition margin delivery.
What Could Make Attention Fade: Repeated test-intensity claims without
incremental financial attribution.
Attention-to-Thesis Conversion: Evaluate company execution and
HBM/Triton attribution independently, then value the resulting cash
stream.

WEAKEST_ASSUMPTION: Additional testing work outweighs productivity
offsets and preserves supplier economics.
MOST_IMPORTANT_DATA_POINT: New DRAM/HBM and Systems/Triton attribution
alongside adjusted-margin reconciliation.
NEXT_DATA_POINT: October 28 at 1:25 p.m. Pacific. Revenue below $260m
together with adjusted margin below 52.5%, absent a quantified timing
bridge, weakens execution. Missing attribution alone is unresolved,
not evidence of vanished demand.

## CROSS_OBJECT_ATTENTION_COMPARISON

Cross-Object Attention Comparison

Cleanest Attention Trade: analytical retention/economics split, not a
validated security trade. Most Evidence-Backed: AEHR for the new
order; FORM for prior realized attribution, different questions. Most
Crowded: unavailable. Highest Fade Risk: TER's narrative without
quantified conversion. Best Durable Thesis: unresolved until
economics, cash and valuation are compared. Raising urgency can
indicate greater uncertainty, not greater expected return.

## 7_DAY_RESEARCH_WORKFLOW

Review by October 15, 2026 or earlier relevant disclosure. Retrieve
current issuer indexes and follow dated links; do not guess future
filing URLs. AEHR: https://www.aehr.com/press-releases/ ; TER:
https://investors.teradyne.com/news-events/press-releases ; FORM:
https://investors.formfactor.com/press-releases . Retain publication
time separately from the fiscal period.

### AEHR — 7-Day Checks

- Build order ID/program | product scope | announcement date |
procurement date if disclosed | delivery window | shipments |
recognized revenue | removals/cancellations. Do not infer the unnamed
customer's identity.
- Reconcile opening backlog + nonoverlapping additions −
issuer-defined removals ± disclosed adjustments. Keep
shipped-but-unrecognized value separate; missing inputs mean an
incomplete bridge, not an invented balance.
- Ask whether any margin change is mix, pricing, utilization or
timing. Do not attribute it to competition without supporting
evidence.

### TER — 7-Day Checks

- Extract SEMICON West technical/customer materials only if published.
Record whether each claim is vendor, customer or independent
measurement.
- Compare Sonoma and Titan using matched device/workload, stress
coverage/duration, temperature control, throughput, slot utilization,
handling, footprint and consumables. Normalize total cost per screened
device; retain unknown cells.
- Separate new spend, replacement spend and revenue shifted within
TER. Prior SLT customers are not a disclosed burn-in customer count.

### FORM — 7-Day Checks

- Prepare October 28 guide-versus-actual fields for revenue and
adjusted gross margin, retaining GAAP separately.
- Preserve the DRAM increment denominator and separately request
HBM/Triton attribution; do not substitute the entire line for either
component.
- Identify any new primary evidence that actually links upstream
economics to this packaged-device rivalry. Without it, leave the
spillover hypothesis unconfirmed.

### Cross-Object — 7-Day Checks

Return source/date | period/unit/denominator | evidence type |
previous → current | retention effect | economics effect | execution
effect | urgency-rank effect | missing input | next review. Preserve
October 5's HBM/execution tests as separate records. If NO_NEW_DATA,
retain pending states and set the next review seven calendar days
after the actual review date, or an earlier confirmed future event;
never reuse an elapsed checkpoint.

Primary-source retrieval registry: AEHR:
https://www.aehr.com/press-releases/ ; TER:
https://investors.teradyne.com/news-events/press-releases ; FORM:
https://investors.formfactor.com/press-releases . Exact historical
financial and new commercial sources appear in the matrix/cards.

Attention-source retrieval registry: AEHR:
https://x.com/PhotonCap/status/2107858654481490184 ; TER:
https://x.com/Schulz_Research/status/2107576569330028695 ; FORM:
https://x.com/carrioresearch/status/2107385517767643533

Evidence-state snapshot: AEHR=order retention supported/economics
pending; TER=deployment supported/scale pending; FORM=prior
attribution unchanged/next execution pending;
classification=trackable_wow; rule=source evidence changes only the
verdict it resolves.

## 30_DAY_RESEARCH_WORKFLOW

Calendar horizon November 7, 2026 is a Saturday; review at the first
existing weekday wake on/after it, November 9, unless relevant
disclosures warrant earlier updates. FORM October 28 and AEHR November
2 lie inside this horizon. Aehr's reporting quarter ended September
25, before the Sonoma announcement: request subsequent order/backlog
commentary without assuming October orders were already revenue. A
six-month delivery plan need not finish in thirty days.

### AEHR — 30-Day Checks

Validate: disclosed order continuity and conversion consistent with
the stated delivery plan. Upgrade economic resilience only with
comparable profitability/cash evidence. Downgrade: material pushout,
cancellation, lost next-generation design or adverse economics; label
which verdict changes. Invalidate a claim of pricing protection if
verified retained-business economics contradict it, rather than
rewriting the original retention claim. Missing confidential pricing
leaves the question pending.

### TER — 30-Day Checks

Validate: production capability with credible matched coverage.
Upgrade: attributable paid adoption and incremental earnings evidence.
Downgrade: disclosed coverage or cost shortcomings. Invalidate the
asserted cost advantage if comparable customer/technical evidence
refutes it; do not invalidate deployment merely because revenue is
undisclosed. Keep the prior consolidated execution and HBM tests
independent.

### FORM — 30-Day Checks

Validate: delivery against the original revenue and adjusted-margin
ranges. Upgrade attributable-growth confidence only with fresh
HBM/Triton evidence. Downgrade execution on the joint below-floor
result without quantified timing repair. Invalidate a specific growth
explanation if the issuer contradicts its attribution; no fresh split
means unresolved. A separate upstream role is not a valuation floor.

### Cross-Object — 30-Day Checks

Rebuild urgency after closing questions; improvement can lower
urgency. Preserve original claims, failed tests and dissenting
evidence. Before an allocation conclusion, request as-of price,
normalized earnings/cash, share count/dilution, scenario probabilities
and downside bridge for each object. Compare outcomes separately from
research status.

For prospective price tracking, use October 8 regular closes for the
three stocks and preselected QQQ if publication precedes that close;
otherwise the next regular close with reason recorded. Use consistent
adjusted prices at the first regular close on/after the
seven/thirty-day horizon. Premarket references above are not return
baselines. Missing consistent adjustment/session data means
unavailable, not a fabricated result. Price appreciation or
benchmark-relative performance in this small sample is not proof of
alpha.

## WKAP DAILY TOP 3

Three market sources worth feeding into today’s market chat. Not
required reading — WKAP has already extracted the signal.

### 1. @PhotonCap — Retained Procurement Is Not Protected Pricing

URL: https://x.com/PhotonCap/status/2107858654481490184
WKAP signal: October 7 interpretation separates stronger rivalry from
a demonstrated lost customer; no holding disclosure visible.
Why it matters today: Aehr's real order supports continuity but leaves
competitive economics unresolved. The post supplies a research
question, not proof of concessions, exclusivity or customer switching.
Themes/tickers: Sonoma, design retention, margin resilience / AEHR.
Question to ask: Which shipment, program and mix-adjusted profit
evidence would distinguish retained growth from weaker value capture?

### 2. @Schulz_Research — Define the Competing Test Before Inferring Share

URL: https://x.com/Schulz_Research/status/2107576569330028695
WKAP signal: October 7 process interpretation localizes Titan
HP/Sonoma overlap to packaged-device burn-in; no holding disclosure
visible.
Why it matters today: It prevents an unsupported company-wide
substitution claim, while leaving comparable coverage, procurement
timing and paid adoption to primary-source verification.
Themes/tickers: Integrated testing, capability versus displacement,
cost per screened device / TER, AEHR.
Question to ask: Which matched coverage and customer-economics
measurements would justify moving from deployed capability to
attributable commercial conversion?

### 3. @carrioresearch — Test Intensity Must Survive the Productivity Offset

URL: https://x.com/carrioresearch/status/2107385517767643533
WKAP signal: October 6 technical Article connects test volume, steps,
duration and cost while recognizing parallel-testing efficiency; no
holding disclosure visible. Forward valuation upside is not adopted.
Why it matters today: FORM's upstream role deserves its own earnings
test, not automatic spillover or automatic benefit. The next result
must separate net demand, attribution and normalized profitability.
Themes/tickers: Wafer probing, HBM/Triton attribution, parallelism / FORM.
Question to ask: What newly disclosed mix and productivity evidence
explains repeatable revenue and margin without treating an HBM
contribution to growth as total HBM sales?

WKAP Radar Feed - 2026 - 10 - 08

Agent-readable facts